The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...
New API discovery and protection capabilities are aimed at helping customers secure distributed applications that span on-premises and cloud locations. F5 is reinforcing application security with a ...
Priority Review granted for CUTX-101 could expedite its path to market, potentially becoming the first FDA-approved treatment for Menkes disease. Cyprium is eligible to receive up to $129 million in ...
FDA assigned PDUFA target action date of July 7, 2026. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN. Atacicept received FDA Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results